



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

5 May 2010
EMA/241053/2010
Human Medicines Development and Evaluation

European network of paediatric research (EnprEMA)

Recognition criteria for self assessment

The European Medicines Agency is tasked with developing a European paediatric network of existing national and European networks, investigators and centers with specific expertise in the performance of studies in the paediatric population.

Following a test pilot phase, public consultation and the outcome of the second workshop with participants of 28 networks and/or clinical trial centres in March 2010, recognition criteria have been finalised which will have to be fulfilled by existing networks to become a member of the European paediatric network. All networks wishing to become a member of EnprEMA are invited to perform self-assessment and to send the filled-in document to the European Medicines Agency.

The document should be sent to Merja.Heikkurinen@ema.europa.eu

END OF SELF-ASSESSMENT PERIOD	31 July 2010
--------------------------------------	--------------



EnprEMA

European network of paediatric research at the European Medicines Agency

Recognition criteria for self-assessment

The European Paediatric Regulation (EC) No 1901/2006, as amended, calls for the fostering of high-quality ethical research on medicinal products for use in children. This should be achieved through efficient inter-network and stakeholder collaboration. To meet this objective, a European paediatric research network is to be formed of national and European networks, investigators and centres with specific expertise in performing drug trials in the paediatric population. General information can be found at:

<http://www.emea.europa.eu/htms/human/paediatrics/network.htm>

Minimum criteria that have to be fulfilled to be recognised as a member of the EnprEMA

This document defines 6 criteria with several subcategories (items) for self-assessment. The criteria and their items have been set up in a public process. Minimum criteria were defined that networks should fulfil to be recognised as a member of the EnprEMA. The defined minimum criteria are flagged with a superscript "M".

Irrespective of whether or not only minimum criteria / items are fulfilled, the full list of the criteria and items as well as the network identification should be completed to the extent possible.

Use of the document and application of the recognition criteria

The criteria should be reported for the highest level that the network currently attains. Networks should report on the status of the network, not on individual investigators or sites. For the purpose of this document, the highest level is called the reporting party.

The document should be filled in by the reporting party (once only per network), taking into account the guidance text provided for the various items within the respective criterion. For transparency in general and to permit public scrutiny of the self-assessment, the completed document should be made public by the reporting party, for example, on their website.

For the same purpose, the reporting party should also make publicly accessible the actual data on which the statements are based. For example, if numbers of paediatric trials are provided, references to clinical trial registration numbers could be made publicly accessible.

The self-assessment should be updated annually.

This document should be sent to the European Medicines Agency; it will be published on the EMA webpage.

Criteria for the recognition of an investigator*, site* or network as a member of the EnprEMA

* only when the investigator or the site is not part of a network

Identification M

Name	Swedish Paediatric Society (BLF)	Include legal address, define acronyms
Type	National network with the majority of paediatricians in Sweden. BLF is working to promote the development of paediatrics in Sweden and ensure high quality health care for children and adolescents. One task force is Medicines for Children and patientsafety.	Indicate type of reporting party, e.g. national or speciality network. May include short mission statement
Street	Att: Synnove Lindemalm Elevhemmet H2:03 Karolinska University Hospital	
Postal code	171 76	
Town	Stockholm	
Country	Sweden	
Telephone 1	+46851770000	
Telephone 2		
Mobile phone	+46739660807	
Fax		
Web site	http://blf.net/blf_ny/valkommen/valkommen.htm	If available (see criterion 4)
Email for general enquiries		If available (see criterion 4)
Representative (main) contact	---	Include first and second name, email, telephone, address, as far as available
First name	19SySynnove	
Second name	Lindemalm	
Telephone	+46851770000	
Mobile phone	+46739660807	
Email	synnove.lindemalm@karolinska.se synnove.lindemalm@gmail.com	
Further contact(s)	---	Include first and second name, email, telephone, address, as far as available
First name		
Second name		
Telephone		
Mobile phone		
Email		

Name	Swedish Peadiatric Society (BLF)	Include legal address, define acronyms
The data in this document are 'current' as of	July 2 nd 2010	Provide the date when the criteria were last updated
State how this document can be accessed by the public	http://blf.net	This should be a link to a webpage, but other means and formats to make public are possible

Description ^M

Year of foundation	The Swedish Peadiatric society was born 1900 but the group within the society working with patient safety and medication fro children was formed in 2010.	Of the network, or of the investigator's or site's specific paediatric research activities
Paediatric age ranges of study participants covered by the network		
Preterm and / or term newborn	☒ Yes ☐ No	Newborn: from birth to less than 28 days of age
Infants from 1 month to less 24 months of age	☒ Yes ☐ No	
Children from 2 years to less than 12 years of age	☒ Yes ☐ No	
Adolescents from 12 years to less than 18 years	☒ Yes ☐ No	
Specialities / Conditions covered	BLF covers all specialities for children but from a paediatric prospective. We have special knowledge in patientsafety and medicinal products for all children 0-18. We have a thorough coporation with pharmacists and nurses in Sweden, and a special center at Astrid Lindgrens Children's Hospital in Stockholm.	ENPREMA will cover a range of different networks, from single speciality trials groups to those covering all paediatrics. If not all areas within one speciality are covered, specify conditions
Multispeciality? Specify	Patientsafety and Medicinal products for children.	For example, oncology or infectious diseases
Speciality or disease specific? Specify	All speciality	For example, cardiology only
Conditions covered? Specify	All conditions	E.g. hypertension (within cardiology) or asthma (within respiratory diseases)
Procedure / intervention specific? Specify	All procedure and interventions.	For example, surgery, organ or stem cell transplantation

Year of foundation	The Swedish Peadiatric society was born 1900 but the group within the society working with patient safety and medication fro children was formed in 2010.	Of the network, or of the investigator's or site's specific paediatric research activities
Number of collaborating countries	List all collaborating countries:	State the number of collaborating countries. Indicate "1" if national; Indicate if Europe, outside of Europe, other..... (describe)
Number of collaborating centres	List all collaborating centres:	State the number of collaborating centres and provide a list of all collaborating centres (attachment or link possible)
Type of activity/studies		
Clinical studies	☒ Yes ☐ No	
Experimental research	☐ Yes ☒ No	
Other activity	We were responsible for tha national survey in Sweden regaring medicinal products for children. We also perfom research in patient safety like Global trigger tool, computer order entry, new procedures and indications, new formulations. We also participate in a nationl work to improve safety in orders and i planning a work to build a formulare for children in Sweden.	Describe type of activities other than clinical and/or non-clinical studies

Evidence for each criterion

Criterion 1: Research experience and ability	7
Criterion 2: Efficiency requirements.....	10
Criterion 3: Scientific competencies and capacity to provide expert advice	12
Criterion 4: Quality management	13
Criterion 5: Training and educational capacity to build competences.....	14
Criterion 6: Public involvement	15

How to provide evidence

1. The evidence for this self-assessment document should be based only on the activity of the network during in the last 5 years.
2. Evidence used in this document should have a reference (e.g., publication, annual or periodic report or internal network document).
3. The self-assessment document is to cover a range of different network types. It is recognised that some networks may not be able to accurately respond to every item. In such circumstances, state why it is not possible to respond.
4. The network is referred to as the “reporting party”.

Criterion 1: Research experience and ability

Do not include planned trials, but only ongoing and completed trials.

1.1 Number of completed trials ^M Number of ongoing trials ^M	One completed trial in collaboration with Swedish Product Agency. Tree ongoing trials.	Any interventional clinical trial, whether non-commercial, investigator-initiated, industry-sponsored or commercial, in which the reporting party actively took part. Minimum requirement (^M): one ongoing or one completed trial.
1.2 Total number of participants actually recruited each year Proportion of eligible participants actually recruited each year Describe way of screening and participant recruitment	3000 patients We sent out a formulary to all units in Sweden with health care for children.	Relevant to speciality specific networks. State total recruitment capacity for any interventional clinical trial, whether non-commercial, investigator-initiated, industry-sponsored or commercial, in which the reporting party actively took part. Which strategies or pathways are used to screen and recruit participants?
1.3 Total number of collaborating centres	Depending.	For completed and ongoing (open) paediatric trials. Do not include sites in set-up.
Academic (investigator) initiated studies	---	Studies conducted independently from pharmaceutical companies (no sponsorship and no funding). There is a separate category (below) for industry-funded studies.
1.4 Number of ongoing and completed clinical trials	Absolute number: Proportion of all studies:	Paediatric interventional trials of any phase of the pharmaceutical development (phase I to IV, including therapy optimising trials if requiring authorisation by regulatory authority) (for other Paediatric trials unrelated to drug development see below)

1.1 Number of completed trials ^M Number of ongoing trials ^M	One completed trial in collaboration with Swedish Product Agency. Tree ongoing trials.	Any interventional clinical trial, whether non-commercial, investigator-initiated, industry-sponsored or commercial, in which the reporting party actively took part. Minimum requirement (^M): one ongoing or one completed trial.
1.5 Number of paediatric specialities covered by paediatric trials		Count specialities, without repetition, across all ongoing or completed paediatric trials
1.6 Number of paediatric conditions covered by paediatric trials		If not all areas within one speciality covered count conditions, without repetition, across all ongoing or completed paediatric trials
1.7 Number of other ongoing research studies / programs	Four.	For example, epidemiological studies, outcome studies, translational research in which the reporting party is participating Include cohort studies but not audits. Research is defined as a project with a specific research question in which the participant/family provides formal consent.
1.8 Indicate the proportion of public funding	Proportion of academic initiated studies: 100 Proportion of budget: 100	Indicate the proportion of the budget handled for completed and ongoing paediatric trials that is derived from public funding sources such as governmental programs, competitive public grants, university contributions
1.9 Number of registered study participants (all studies)	3000+2 000 000	
Industry-sponsored trials	---	
1.10 Number of ongoing and completed trials	0	Paediatric interventional trials of any phase of the pharmaceutical

1.1 Number of completed trials ^M Number of ongoing trials ^M	One completed trial in collaboration with Swedish Product Agency. Tree ongoing trials.	Any interventional clinical trial, whether non-commercial, investigator-initiated, industry-sponsored or commercial, in which the reporting party actively took part. Minimum requirement (^M): one ongoing or one completed trial.
		development (phase I to IV, including therapy optimising trials if requiring authorisation)
1.11 Number of paediatric specialities covered by paediatric trials		Count specialities, without repetition, across all ongoing or completed paediatric trials
1.12 Number of paediatric conditions covered by paediatric trials		If not all areas within one speciality covered count conditions, without repetition, across all ongoing or completed paediatric trials
1.13 Number of registered study participants (all studies)		

Criterion 2: Network organisation and processes

2.1 Existence of an identified contact person for external enquiries ^M	☒ Yes ☐ No Comments:	Enquiries from patients, parents, organisations, researchers, pharmaceutical companies or regulatory authorities are co-ordinated or answered by a nominated contact person. Provide contact details in section "Identification" above.
2.2 Existence of an internal steering committee ^M	☒ Yes ☐ No Comments:	Minimum requirement (^M): either an internal steering committee (2.2) or an external advisory / steering committee (2.3).
2.3 Existence of an external advisory / steering committee directing the reporting party ^M	☐ Yes ☒ No Comments:	Minimum requirement (^M): either an internal steering committee (2.2) or an external advisory / steering committee (2.3).
2.4 Existence of a website	☒ Yes ☐ No Comments:	If available, mention in "identification" above
2.5 Existence of newsletter	☒ Yes ☐ No Comments:	Newsletter of any format (electronic, surface mail), distributed actively to selected recipients.
2.6 Existence of an internal database(s) for disease, condition, treatment and / or outcome ^M If yes, please describe	☒ Yes ☐ No Comments / description: We have several in Sweden.	For example, data base or disease registry to facilitate planning or conducting future trials (may or may not contain individual patient data)
2.7 Provisions to ascertain data protection and data security ^M	☒ Yes ☐ No Comments:	Are provisions in place to ascertain patients' /study participants' data protection and data safety within network
2.8 Procedure(s) to access the database by third parties	☐ Yes ☒ No Comments: After agreements with the owners of the specific databas and after approval from ethic committée.	Are provisions in place that data can be shared for planning, conducting or analysing a trial(s)?

2.1 Existence of an identified contact person for external enquiries ^M	☒ Yes ☐ No Comments:	Enquiries from patients, parents, organisations, researchers, pharmaceutical companies or regulatory authorities are co-ordinated or answered by a nominated contact person. Provide contact details in section "Identification" above.
2.9 Access to external databases /registries	☒ Yes ☐ No Comments:	For example, national databases that are not publicly accessible but to which the reporting party has open or privileged access; database(s) immediately relevant to area and / or scope
2.10 Standardised process to access an external database(s)	☐ Yes ☒ No Comments:	Is a standardised process in place to access external/ national databases?

Criterion 3: Scientific competencies and capacity to provide expert advice

3.1 Number of peer-reviewed publications in the last 5 years Provide exact reference(s) Describe the network's contribution to publication(s)	1 and several ongoing. Drug related problems and off-label drug treatment in children as seen at a drug information centre. Kimland E, Bergman U, Lindemalm S, Böttiger Y. Eur J Pediatr. 2007 Jun;166(6):527-32. Epub 2006 Dec 29 Supervising.	The publications should indicate that they are related to and reference the reporting party.
3.2 Number of competitive grants obtained in the last 5 years	0	Grants obtained by reporting party (exclusively or not).
3.3 Access to expert groups ^M	☒ Yes ☐ No Comments: In collaboration with authorities.	Indicate if the reporting party has specific access to established expert groups, such as learned societies
3.4 Capacity to answer external scientific questions ^M	☒ Yes ☐ No Comments:	Indicate if coordinated capacity (staff, process) is available to answer external scientific questions in relation to clinical trials during daily business.
Standardized procedures for assessment of:	---	
3.5 Site feasibility	☐ Yes ☒ No Comments:	This concerns the suitability of a site for conducting a given trial
3.6 Participant recruitment	☐ Yes ☒ No Comments:	This concerns provisions to regularly monitor recruitment progress for a trial.
3.7 Budget calculation for studies	☐ Yes ☒ No Comments:	This concerns, for example, quotes and prospective financial planning for a trial.

Criterion 4: Quality management

4.1 Documented adherence to Good Clinical Practice (GCP) guideline ^M	☒ Yes ☐ No Comments:	Declare whether studies conducted comply with the EU Directive 2001/20/EC on Clinical Trials.
4.2 Documented adherence to the ethical considerations for clinical trials in children ^M	☒ Yes ☐ No Comments:	Indicate if documented data / information are publicly available on implementation of / provisions for special ethical requirements for the paediatric trial(s) according to the document " Ethical considerations for clinical trials on medicinal products conducted with the paediatric population ".
4.3 Documented adherence to ethical considerations	☒ Yes ☐ No Comments:	Declare whether reporting party requests approval by an independent ethics committee with paediatric expertise for all studies conducted.
4.4 Availability of Standard Operation Procedures (SOP)	☐ Yes ☒ No If yes, provide reference to available SOPs	Indicate existence of SOP e.g. for study management, adverse events reporting etc.
4.5 Capacity to monitor studies (academic trials, industry sponsored trials) ^M	☐ Yes ☒ No Comments:	Indicate if the reporting party implements the monitoring of paediatric trials according to ICH 6 Good Clinical Practice Guideline.
4.6 Capacity to monitor performance of collaborating centres	☐ Yes ☒ No Comments:	Indicate if the reporting party implements the monitoring of performance of collaborating centres.
4.7 Quality control and quality assurance, traceability and data safety ^M	☒ Yes ☐ No Comments:	Indicate if this is implemented in the reporting party's remit.

Criterion 5: Training and educational capacity to build competences

5.1 Evidence of collaboration with regulatory authorities ^M	☒ Yes ☐ No Comments:	Indicate awareness of regulatory requirements for developing medicines; for example, implementation of guidelines from regulatory authorities.
5.2 Capacity to provide competent consultation to regulatory authorities	☒ Yes ☐ No Comments:	Indicate the capacity of the reporting party to provide expert advice to regulatory authorities. For example, nominations into standing scientific committees to regulatory authorities, registration(s) as authorities' external expert(s).
5.3 Formal meetings for clinical trials If yes, provide number	☐ Yes ☒ No Comments:	For example, investigator meetings, trainings specific to a given ongoing or planned trial.
5.4 Training courses given over the last 2 years ^M If yes, provide number	☒ Yes ☐ No Comments: 2	For example, training specific to a trial or in general for trial(s), with external participants or from the reporting party. Minimum requirement (M): training courses either given (5.4) or received (5.5).
5.5 Training courses received over the last 2 years ^M If yes, provide number	☒ Yes ☐ No Comments: 2	For example, training specific to a trial or in general for trial(s), with external participants or from the reporting party. Minimum requirement (M): training courses either given (5.4) or received (5.5).
5.6 Promotion of participation in clinical trials in countries with limited resources Provide list of countries	☐ Yes ☒ No Comments:	Indicate if support for such trials is provided by the reporting party.

Criterion 6: Public involvement ^M

Minimum requirement (M): involvement in at least one of the below items.

6.1 Involvement of patients, parents or their organisations in the protocol design	☐ Yes ☒ No Comments:	Indicate if public stakeholders are /have been involved
6.2 Involvement of patients, parents or their organisations in creating the protocol information package	☐ Yes ☒ No Comments:	Indicate if public stakeholders are /have been involved
6.3 Involvement of patients, parents or their organisations in the prioritisation of needs for clinical trials in children	☒ Yes ☐ No Comments:	Indicate if public stakeholders are /have been involved